Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Table 3 Safety summary

	All patients (N = 60)
≥1 Adverse event of Grade 3 or 4^a, n (%)	23 (38.3)
Increased GGT	5 (8.3)
Increased AST	5 (8.3)
Gastrointestinal bleeding	4 (6.7)
Decrease in white blood cell count	4 (6.7)
Increased bilirubin	5 (8.3)
Decrease in neutrophil count	3 (5)
Ascites	3 (5)
Decrease in platelet count	1 (1.7)
Increased ALT	5 (8.3)
Hyponatremia	2 (3.3)
Pneumonia	1 (1.7)
Type I diabetes	1 (1.7)
Hypokalemia	1 (1.7)
Myocarditis	1 (1.7)
Hypophysitis	1 (1.7)
Bullous dermatitis	1 (1.7)
Hypertension	2 (3.3)
Grade 5^b adverse event, n (%)	1 (1.7)^b

^aAdverse events were graded according to the Common Terminology Criteria for Adverse Events v4.0; ^bone patient whose main cause of death was immune hepatitis, and who died after treatment with high-dose hormone shock and liver protection
ALT alanine transaminase, AST aspartate transaminase, GGT Gamma-glutamyl transferase

ISSN: 2050-7771